GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Capex-to-Operating-Income

Essex Bio-Technology (HKSE:01061) Capex-to-Operating-Income : 0.39 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Essex Bio-Technology's Capital Expenditure for the six months ended in Dec. 2024 was HK$-69.70 Mil. Its Operating Income for the six months ended in Dec. 2024 was HK$180.28 Mil.

Hence, Essex Bio-Technology's Capex-to-Operating-Income for the six months ended in Dec. 2024 was 0.39.


Essex Bio-Technology Capex-to-Operating-Income Historical Data

The historical data trend for Essex Bio-Technology's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Capex-to-Operating-Income Chart

Essex Bio-Technology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.44 0.62 1.01 0.38 0.34

Essex Bio-Technology Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.39 0.38 0.29 0.39

Competitive Comparison of Essex Bio-Technology's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Essex Bio-Technology's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's Capex-to-Operating-Income falls into.


;
;

Essex Bio-Technology Capex-to-Operating-Income Calculation

Essex Bio-Technology's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-119.471) / 355.084
=0.34

Essex Bio-Technology's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-69.698) / 180.281
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology  (HKSE:01061) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Essex Bio-Technology Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines